The “Turkish Pharma Sector Report”, prepared for the second time by IQVIA with the support of AIFD and the European Federation of Pharmaceutical Industries and Associations (EFPIA), closely monitors the trends and developments in the sector
03.12.2024
The “Turkish Pharma Sector Report 2024” prepared by IQVIA under the sponsorship of AIFD and EFPIA was shared with the public. This report, prepared regularly every year, provides an in-depth analysis of the Turkish pharmaceutical sector with objective and comparative annual data. The report includes up-to-date, detailed analyses on topics ranging from the size of the global pharmaceutical market to healthcare expenditures, reimbursement processes, and key components of the pharmaceutical value chain such as production, foreign trade, investment, and R&D activities.
The report, prepared for the second time, closely monitors the trends and developments in the sector
First published last year and planned to be prepared regularly every year, the “Turkish Pharma Sector Report” serves as an important reference source for the healthcare sector and the academic community.
AIFD Economic Policies Director Serah Kekeç, said that a correct understanding of the Turkish pharmaceutical sector is very valuable for the development of the ecosystem and made the following statements about the report: “The 2024 Turkish Pharma Sector Report presents independent research, analyses, comparisons with similar countries, and insights related to both the Turkish and global pharmaceutical sectors. In this respect, it not only highlights areas that need improvement but also serves as a guide to advance our sector. With the help of objective data shared regularly each year, it becomes possible to analyze needs. We are pleased that the Turkish Pharma Sector Report is recognized as a reference source for all stakeholders contributing value to our country’s healthcare ecosystem. As AIFD, our report, which is one of our efforts to contribute to finding effective solutions to health issues in our country, in a way closely monitors the trends and developments in the sector. We will continue our efforts in line with our vision to ensure timely and sustainable access to innovative medicines and treatments in Türkiye, to lead the development of a dynamic pharmaceutical sector, and to enhance our country’s global competitiveness in medical/pharmaceutical R&D.”